BCL2 and lymphoma: Moreover, our cross-species strategy also linked the GCB subtype of DLBCL samples at diagnosis, i.e. prior to any drug encounter, to a set of TIS-upregulated genes, thereby matching our previous experimental observation of a particularly strong TIS capacity in GCB-like and Bcl2-overexpressing, but not in ABC-like Eμ-myc lymphomas with their enrichment of “TIS down-regulated” and proliferation-associated gene sets27 (Fig. 5f).